Haemophilus influenzae (H. influenzae) are bacteria commonly carried in the respiratory tract, which can cause acute invasive disease. They are divided into encapsulated and unencapsulated (non-typeable) strains. Encapsulated strains can be classified into six serotypes, from a to f, of which type b (Hib) was most prevalent prior to vaccine introduction. Infection with H. influenzae can cause the following conditions:
- acute respiratory infections
Less frequent conditions which may be caused by H. influenzae infection include:
- septic arthritis
For more information on H. influenzae, visit the NHS inform website.
Guidance on Haemophilus influenzae can be found below:
- For more information on Haemophilus influenzae type b (Hib) immunisation, including updates, please refer to the Public Health England (PHE) Green Book, Chapter 16.
- Find out about Public Health England's management of Hib.
- Training and educational materials for healthcare professionals are on the NHS Education for Scotland (NES) website.
For all infection prevention and control guidance visit the A-Z pathogens section of the National Infection and Prevention Control Manual.
Data and surveillance
In 1992, following introduction of the Hib vaccine for young children, the number of H. influenzae type b cases fell dramatically, not only in the vaccinated group but also in older age groups. Due to reduced carriage of the organism within the respiratory tract of vaccinated children, transmission to the wider community was effectively suppressed. The addition of the Hib booster vaccine in 2006, reduced case numbers further.
In Scotland, typing is conducted on all cases with positive laboratory reports for H. influenzae, in order that national trends in disease subtypes can be monitored. Further enhanced surveillance is carried out for all H. influenzae cases identified in children under the age of 5 and type b strains across all age groups.
Surveillance update for January to March 2019
Between January and March 2019 (weeks 1 to 13), 23 cases of invasive H. influenzae were reported. This is comparable to cumulative case numbers reported over the previous ten years which ranged from 11 to 33 cases, as shown in Figure 1.
Of the 23 cases reported so far in 2019:
- two (8.7%) were aged under five years
- one (4.3%) was aged between 21-30 years
- 20 (87.0%) were above 40 years of age
Information on clinical presentation was available for both paediatric (under 16 years old) cases. One case presented with meningitis, and one case presented with bacteraemia.
Of the 23 invasive cases reported so far in 2019:
- 18 (78.3%) had H. influenzae isolated from blood
- three (13.0%) from cerebrospinal fluid
- two (8.7%) from pleural fluid
No cases are known to have died in 2019, which is comparable to the same period over the previous five years (0 to 1 deaths).
Figure 2 demonstrates the epidemiological impact of the Hib vaccine, for those aged under five (routinely vaccinated group) and for all ages (including under fives). Prevalence has shown a corresponding decrease in cases since 1992 and figures have remained relatively stable since 2011.
Figure 3 presents laboratory reports by serotype, since the introduction of the Hib booster campaign in 2003.
H. influenzae typing was carried out for 16 (69.6%) isolates, of which:
- 14 (87.5%) were non-typeable (NT)
- two (12.5%) were type f
Both paediatric cases were non-typeable.
There continues to be a high proportion of non-typeable (NT) isolates, and isolates not sent for typing.
Vaccine uptake statistics
Vaccine uptake statistics can be found on the Information Services Division (ISD) website.